Key facts
- This page summarizes Silji Abraham's Form 4 filing for WEST PHARMACEUTICAL SERVICES INC (WST).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Feb 2024, 11:37.
Silji Abraham - 23 Feb 2024 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)
- Reporting relationship
- SVP, Chief Technology Officer
- Issuer ticker
- WST
- Reported as of
- 23 Feb 2024
- Net transaction value
- -$1,344,761
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2024, 11:37:24 UTC
- Prior SEC filing
- 22 Feb 2024
- Next SEC filing
- 13 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Luis Cantarero
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Silji Abraham filed Form 4 for WEST PHARMACEUTICAL SERVICES INC (WST) on 27 Feb 2024.
Change
- Previous filing in this sequence was filed on 22 Feb 2024.
- Current net transaction value: -$1,344,761.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
WST
transaction
Common Stock
Options Exercise
- Transaction value
- $1,214,619
- Shares
- +7,012
- Change %
- +150%
- Price
- $173.22
- Shares after
- 11,672
- Date
- 23 Feb 2024
- Ownership
- Direct
WST
transaction
Common Stock
Sale
- Transaction value
- $2,559,380
- Shares
- -7,012
- Change %
- -60%
- Price
- $365.00
- Shares after
- 4,660
- Date
- 23 Feb 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
WST
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -7,012
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Stock Options (Right to Buy)
- Underlying amount
- 7,012
- Exercise price
- $173.22
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This award vests in four equal annual installments beginning on February 18, 2021.